ArticleCureus2025
The Possible Unveiling of Myasthenia Gravis via Allergy Shots.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report discusses subcutaneous allergen immunotherapy (SCIT) for allergic rhinoconjunctivitis and explores whether myasthenia gravis symptoms developed in a patient due to subcutaneous allergen immunotherapy treatment. SCIT is known to induce immune tolerance through the generation of allergen-specific regulatory T and B cells, increased allergen-specific IgG4, and suppression of effector cell responses, resulting in sustained clinical benefit for allergic disease. Although SCIT is considered safe and is not associated with an increased risk of autoimmune disease in large population studies, rare case reports have raised concerns about its potential to trigger autoimmune conditions. The most common triggers for autoimmune diseases, including myasthenia gravis, remain unclear, but allergic diseases themselves may confer an increased risk. This case report highlights the need for further research into the immunological mechanisms and potential triggers of autoimmunity in the context of allergen immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.